EUCTR2014-005341-44-AT进行中（未招募）1 期
Molecular-biological tumor profiling for drug treatment selection in patients with advanced and refractory carcinoma
Medical University of Graz0 个研究点目标入组 64 人开始时间: 2015年3月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male/ female patients with locally advanced and/ or metastasized carcinoma for whom no further evidence-based drug therapy is established.
- •2. Diagnosis of unresectable locally advanced and/or metastatic carcinoma with histologically confirmed disease
- •3. Confirmed progression after evidence-based drug therapy and no option for further evidence-based drug therapy (at least one phase III study) in this indication
- •4. Age >18 years - =85
- •5. Life expectancy of at least 12 weeks
- •6. Measureable disease according to the revised RECIST criteria version 1.1. (Eisenhauer, E.A., et al., New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 2009. 45(2): p. 228-47.) Das ist die Referenz 3
- •7. ECOG score 0-2 (Appendix A)
- •8. Adequate bone marrow, liver and kidney function:
- •laboratory cut-off levels according to the registration of registered drugs (will be checked again before treatment start)
- •9. No anti-tumor therapy including radiotherapy in the past two weeks.
- •10. Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Significant comorbidity which is expected to affect patient's prognosis or ability to receive therapy:
- •a. History of significant cardiovascular disease unless the disease is well controlled. Significant cardiac disease includes second/ third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) class II or worse (slight limitation of physical activity; comfortable at rest but ordinary activity results in fatigue, palpitation or dyspnea).
- •b. History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial.
- •c. Active infection or any serious underlying medical condition that would impair the ability of the patient to receive protocol therapy.
- •d. History of any psychiatric condition that might impair the patient's ability to understand or comply with the requirements of the study or to provide consent.
- •e. Hypersensitivity with anaphylactic reaction to humanized monoclonal antibodies or any of the applied drugs
- •2. Untreated CNS metastases. Patients with treated brain metastases are eligible if they are clinically stable with regard to neurologic function, off steroids after cranial irradiation (whole brain radiation therapy, focal radiation therapy, and stereotactic radiosurgery) ending at least 2 weeks prior to treatment start, or after surgical resection performed at least 28 days prior to treatment start.
- •3. Previously diagnosed malignancies except for adequately treated non-melanoma skin cancer, in situ cancer, or other cancer from which the subject has been disease free for at least 5 years.
- •4. Pregnant or breast feeding
研究者
相似试验
招募中
不适用
The Cancer Molecular Screening and Therapeutics (MoST) Program-ScreeningCancer - Any cancerCancerACTRN12616000908437niversity of Sydney7,628
尚未招募
Unknown
Study for the identification of tumor-relevant biomarkers from visceral and subcutaneous adipose tissue of obese and non-obese patients.E66C00-C97Malignant neoplasmsObesityDRKS00034238Johanniter Krankenhaus Bonn50
进行中（未招募）
不适用
iquid biopsy of brain tumors using cerebrospinal fluid analysisCTRI/2022/06/042986Strand Life Sciences Pvt Ltd
招募中
不适用
Register study of the Molecular Tumor Board (tumor entity-spanning molecular characterization program to evaluate individualized tumor biology-guided therapy in adults with rare and advanced tumor entities)Cross-tumor entity (adult patients = 18 years of age with any advanced tumor disease or with rare tumor entity (incidence of less than one case per 100,000 population)).N/ADRKS00025847niversitätsklinikum Freiburg Klinik für Innere Medizin I Schwerpunkt Hämatologie, Onkologie und Stammzelltransplantation1,000
招募中
Unknown
Biomarker discovery research for malignant tumors using SCRUM-Japan GI/MONSTAR-SCREEN integrated databaseSolid MalignanciesJPRN-UMIN000049334ational Cancer Center Hospital East27,500